Pfizer has released data from a phase 2 clinical trial of an experimental obesity drug acquired through its $10 billion acquisition of Metsera. In a study with 268 patients, the drug in two dosage groups led to more significant weight loss compared to placebo. The first group (2 smaller doses before the 3.2 mg monthly dose) achieved a loss of 10 percentage points more in completers and 8 percentage points, including those who dropped out, after 28 weeks. The second group (3 doses before the 4.8 mg monthly dose) lost 12 percentage points in completers and 11 percentage points overall. The study started with weekly doses and switched to monthly doses after 12 weeks, with an overall weight reduction of up to 11 percent. Side effects were mostly mild or moderate, with one severe case of nausea and one case of vomiting. Pfizer plans to test the 9.6 mg dose in Phase 3 due to good tolerability.[1][2]